Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00184015 |
|
Recruitment Status : Unknown
Verified April 2017 by University of Southern California.
Recruitment status was: Active, not recruiting
First Posted : September 16, 2005
Last Update Posted : April 11, 2017
|
Sponsor:
University of Southern California
Information provided by (Responsible Party):
University of Southern California
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Actual Primary Completion Date : | August 21, 2016 |
| Estimated Study Completion Date : | August 21, 2018 |